Personalis Earnings Call: Growth Push Meets Margin Squeeze

Personalis ((PSNL)) has held its Q1 earnings call. Read on for the main highlights of the call.

Personalis’ latest earnings call struck a nuanced tone, pairing upbeat operational momentum with sobering financial realities. Management highlighted surging minimal residual disease testing volumes, strong clinical adoption, and robust liquidity, yet acknowledged sharp gross margin erosion, rising expenses, and a widening net loss as the company leans into an aggressive investment phase.

Rapid clinical volume acceleration

Personalis reported more than 7,800 clinical tests in the first quarter of 2026, marking a 26% sequential increase over the prior quarter and a steep 258% gain year over year. Management reiterated its ambitious full‑year goal of 43,000 to 45,000 clinical tests, underscoring confidence that current momentum will carry through the rest of 2026.

Strong clinical adoption and retention

The company surpassed 1,000 ordering physicians during the quarter, signaling widening acceptance of its MRD offering among oncologists. Retention remained above 98% over recent quarters, a level that suggests deepening usage patterns and high switching costs as physicians incorporate Personalis’ platform into routine practice.

Compelling clinical and real‑world data

Evidence updates formed a key pillar of the call, with NeoPrism CRC collaborators reporting a 100% negative predictive value for relapse in a colorectal cancer cohort. Real‑world testing in 10,000 patients showed roughly 40% of positive detections in an ultrasensitive range below 100 ppm, while DARWIN II data linked early ctDNA clearance to nearly a fivefold higher chance of remaining progression‑free at three years.

Product and roadmap progress

Beyond basic MRD status, Personalis is expanding into deeper tumor biology insights by piloting a real‑time Variant Tracker tool. This capability is designed to monitor how tumor mutations evolve under therapy, potentially helping clinicians refine treatment decisions and broadening the clinical utility of the company’s platform.

Growing MRD biopharma opportunity

Biopharma MRD revenue reached $3.1 million in the first quarter, and management is targeting $20 million to $21 million for the full year as adoption builds. Strategic revenue, which includes clinical and biopharma MRD usage, totaled $4.5 million in the quarter, with guidance calling for more than a doubling to $30 million to $32 million in 2026.

Reimbursement progress and clinical revenue ramp

Recent Medicare coverage wins for breast and lung cancer surveillance have begun to flow through, helping lift clinical revenue to $1.4 million from only $0.3 million a year earlier. Management emphasized that this roughly 367% growth supports rising average selling prices and should eventually drive margin expansion as a larger share of volumes become reimbursed.

Strong liquidity and runway

The company ended the quarter with $233.2 million in cash and short‑term investments and reported no material debt on the balance sheet. Cash usage in the period was about $28 million, including a one‑time incentive payment of roughly $5 million, providing management with confidence to continue funding its MRD growth strategy despite elevated burn.

Revenue mix shift and topline decline

Total revenue fell to $15.5 million, about 25% lower than the same quarter last year, as Personalis intentionally migrated away from lower‑margin legacy and enterprise work. The company also flagged an expected drop in Moderna‑related revenue following the completion of a large Phase 3 enrollment, deepening the near‑term topline pressure.

Severe gross margin compression

Gross margin contracted sharply to 1.8% from 35% a year earlier, a decline of more than 33 percentage points that management tied largely to unreimbursed testing. The company estimated that over 2,000 basis points of dilution stemmed from running high test volumes ahead of broad payer reimbursement, a strategy it believes will position margins to rebound as coverage catches up.

Rising expenses and widening net loss

Operating expenses climbed to $32.4 million from $24.9 million, with research and development rising to $14.5 million and selling, general and administrative costs jumping to $17.9 million. The net loss nearly doubled to $30.0 million versus $15.8 million a year earlier, reflecting the company’s willingness to absorb heavier losses to accelerate MRD market share gains.

Cash burn and reimbursement risks

Management expects a full‑year net loss of about $105 million and cash usage of roughly $100 million in 2026, signaling continued heavy investment and elevated short‑term burn. Crucially, the path to margin and revenue improvement depends on the timing of additional coverage decisions and payer adoption, leaving the company exposed if MolDX reviews or reimbursement agreements take longer than expected.

Biopharma testing services decline

Biopharma testing services revenue, excluding MRD‑specific gains, fell to $11.2 million from $13.6 million, an approximately 18% decline that management largely attributed to the Moderna wind‑down. The company framed this as a transition phase as it shifts resources away from legacy contracts toward higher‑value MRD partnerships.

Guidance and outlook

Personalis reaffirmed its 2026 revenue outlook of $78 million to $80 million, including $10 million to $11 million of clinical revenue and $20 million to $21 million of biopharma MRD revenue. The company expects full‑year gross margins between 15% and 20%, strategic revenue more than doubling, a net loss near $105 million, and 43,000 to 45,000 clinical tests, framing the first half as the trough for margins as unreimbursed volumes convert.

Personalis’ earnings call painted the picture of a company aggressively trading near‑term profitability for longer‑term position in the MRD market. Investors will be watching closely whether volume growth, reimbursement progress, and clinical data translate into the promised mix shift toward higher‑margin revenue before the cash cushion is meaningfully eroded.